Immune Pharmaceuticals is on a mission to improve patients’ lives through targeted medicine. The company is well-funded by a diverse investment base. Clinical work focuses on severe and/or rare inflammatory diseases and cancer.

What Many Investors May Not Know About IMNP:

  1. Our lead asset, Bertilimumab, is a first in class antibody, with on going phase 2 trials in multiple indications and potential sales of $ 5B per year
  2. Our Immuno-Oncology pipeline, includes 3 mid-to-late stage assets and two platforms with a focus on check point inhibitors.
  3. NanoCyclo is a potentially game changing topical treatment for atopic dermatitis and psoriasis with potential sales of $1B and 505(b)2 accelerated track.
  4. IMNP NYC based new management team is poised for execution with multiple 2016-17 milestones.

Information to the Swedish Markets, June 2015

Holdings of Insiders, as of latest reported date

Insider Name Relationship Total Holdings
Teper, Daniel Gedeon Chief Executive Officer 5,865,280
Kazado, Daniel Director 907,290
Luchi, Monica E Officer 777,778
Paley, Jeffrey Director 8,000
Militello, John CPA Officer 2,000
Neczesny, John A Director 0
Ben-Ami, Miri Officer 0